Zai Lab (ZLAB) Competitors

Zai Lab (NASDAQ:ZLAB) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Which has better valuation & earnings, ZLAB or GMAB?

Genmab A/S has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$427.80M	8.42	-$257.10M	-$2.04	-15.79
Genmab A/S	$3.12B	5.16	$1.14B	$1.99	12.62

Do analysts prefer ZLAB or GMAB?

Zai Lab currently has a consensus target price of $56.35, indicating a potential upside of 74.89%. Genmab A/S has a consensus target price of $37.60, indicating a potential upside of 49.74%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts clearly believe Zai Lab is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Does the media prefer ZLAB or GMAB?

In the previous week, Zai Lab had 3 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Zai Lab and 5 mentions for Genmab A/S. Zai Lab's average media sentiment score of 1.07 beat Genmab A/S's score of 0.58 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ZLAB or GMAB?

Zai Lab has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in ZLAB or GMAB?

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 5.0% of Zai Lab shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is ZLAB or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Zai Lab's net margin of -49.68%. Genmab A/S's return on equity of 21.03% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-49.68%	-27.32%	-18.85%
Genmab A/S	37.53%	21.03%	16.98%

Summary

Zai Lab and Genmab A/S tied by winning 8 of the 16 factors compared between the two stocks.